Condition category
Nervous System Diseases
Date applied
21/05/2010
Date assigned
21/05/2010
Last edited
08/08/2016
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Ms Claudia Wheeler-Kingshott

ORCID ID

Contact details

The Institute of Neurology
Queen Square
London
WC1N 3BG
United Kingdom
-
c.wheeler-kingshott@ion.ucl.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

5580

Study information

Scientific title

Development of novel magnetic resonance imaging (MRI) techniques for neurological applications

Acronym

Study hypothesis

Quantitative magnetic resonance imaging (MRI) techniques may provide additional information in the understanding of several neurological and psychiatric disorders. The development of some of these techniques is still incomplete and the interpretation of results in pathology is thus limited. Scanning healthy subjects and analysing their data will help in making the scanning techniques suitable for clinical applications. This is an ongoing process of continual testing and optimisation.

Ethics approval

MREC, ref: 05/Q0502/101

Study design

Single-centre non-randomised observational diagnosis and screening study

Primary study design

Observational

Secondary study design

Non randomised controlled trial

Trial setting

Hospitals

Trial type

Screening

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Topic: Neurological; Subtopic: Neurological (all Subtopics); Disease: Nervous system disorders

Intervention

Routine MRI examinations only provide qualitative images of the brain. Quantitative MRI techniques, such as MR spectroscopy (MRS), magnetisation transfer imaging (MTI), diffusion imaging (DI), perfusion imaging (PI) and relaxometry can be particularly useful in the investigation of the pathological substrate of several diseases. Their usefulness is well documented in the literature; however, their application is somehow limited by technical problems.

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

1. Magnetic resonance imaging (MRI)
2. MR spectroscopy (MRS)
3. Magnetisation transfer imaging (MTI)
4. Diffusion imaging (DI)
5. Perfusion imaging (PI)

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/01/2006

Overall trial end date

31/07/2009

Reason abandoned

Eligibility

Participant inclusion criteria

Not provided at time of registration

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

Planned sample size: 150

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

01/01/2006

Recruitment end date

31/07/2009

Locations

Countries of recruitment

United Kingdom

Trial participating centre

The Institute of Neurology
London
WC1N 3BG
United Kingdom

Sponsor information

Organisation

University College London (UCL) (UK)

Sponsor details

UCL Biomedicine Research & Development Unit
Maple House
149 Tottenham Court Road
London
W1T 7NF
United Kingdom

Sponsor type

University/education

Website

http://www.ucl.ac.uk/

Funders

Funder type

Charity

Funder name

Multiple Sclerosis Society (UK)

Alternative name(s)

MS Society

Funding Body Type

private sector organisation

Funding Body Subtype

professional associations and societies

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

09/08/2016: No publications found, verifying study status with principal investigator.